Atifah Safi

Atifah Safi is a patent litigation attorney with a practice focused predominantly on the life sciences sector, including pharmaceuticals, biologics, and medical devices. Her academic background, holding a B.S. in Biochemistry from the University of Maryland, College Park, provides a strong technical foundation for her work in these complex scientific fields. She has experience representing pharmaceutical companies in Hatch-Waxman and other patent infringement disputes.

Ms. Safi's litigation experience includes representing both plaintiffs and defendants. While her firm, Desmarais LLP, primarily represents branded drug and biologic manufacturers, her tracked cases show appearances on both the plaintiff (1 case) and defendant (2 cases) sides, indicating versatility in her litigation approach.

Currently an Associate at Desmarais LLP, Ms. Safi previously gained experience as an Associate at Kirkland & Ellis LLP from 2022 to 2024. A notable aspect of her practice includes her involvement as a team member representing Sun Pharmaceutical Industries Inc. in a significant victory before the U.S. International Trade Commission. In this matter, the Commission found Biofrontera's RhodoLED XL system to infringe Sun Pharmaceutical's patents, issuing limited exclusion orders and cease-and-desist orders against the importation and sale of infringing products.

While specific details of Ms. Safi's individual IPR appearances are not explicitly detailed, her firm, Desmarais LLP, has significant experience in Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB), particularly within the life sciences and medical device fields. Ms. Safi was admitted to the District of Columbia Bar in 2022 and earned her J.D. from the University of Virginia School of Law in 2022, where she served on the Editorial Board of the Virginia Law Review.